References

  • • https://www.ahajournals.org/doi/full/10.1161/01.CIR.98.12.1158

  • • Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006 May-Jun;13(3):387-96. doi: 10.1097/01.gme.0000179049.08371.c7. Erratum in: Menopause. 2006 Sep-Oct;13(5):850. Ribot, Jean [corrected to Ribot, Claude]. PMID: 16735935. https://pubmed.ncbi.nlm.nih.gov/16735935/

  • • Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017 Apr 1;177(4):471-479. doi: 10.1001/jamainternmed.2016.9539. Erratum in: JAMA Intern Med. 2017 Apr 1;177(4):600. Erratum in: JAMA Intern Med. 2019 Mar 1;179(3):457. PMID: 28241231; PMCID: PMC5433755. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433755/

  • • https://www.nejm.org/doi/full/10.1056/nejmoa1506119

    • Peter J. Snyder, M.D., Shalender Bhasin, M.D., Glenn R. Cunningham, M.D., Alvin M. Matsumoto, M.D., Alisa J. Stephens-Shields, Ph.D., Jane A. Cauley, Dr.P.H., Thomas M. Gill, M.D., Elizabeth Barrett-Connor, M.D., Ronald S. Swerdloff, M.D., Christina Wang, M.D., Kristine E. Ensrud, M.D., M.P.H., Cora E. Lewis, M.D., M.S.P.H., et al., for the Testosterone Trials Investigators, Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; 374:611-624 DOI:10.1056/NEJMoa1506119 https://www.nejm.org/doi/full/10.1056/nejmoa1506119

  • • Donovitz GS. A Personal Prospective on Testosterone Therapy in Women-What We Know in 2022. J Pers Med. 2022 Jul 22;12(8):1194. doi: 10.3390/jpm12081194. PMID: 35893288; PMCID: PMC9331845. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331845/

    • Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999 Dec;44(12):1012-20. PMID: 10649811. https://pubmed.ncbi.nlm.nih.gov/10649811/

    • https://medicinaysaludpublica.com/noticias/general/testosterone-insufficiency-and-treatment-in-women-international-expert-consensus/5093

    • Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019 Oct;7(10):754-766. doi: 10.1016/S2213-8587(19)30189-5. Epub 2019 Jul 25. PMID: 31353194. https://pubmed.ncbi.nlm.nih.gov/31353194/

    • Abdulmaged M. Traish and Abraham Morgentaler. Androgen Therapy in Women with Testosterone Insufficiency: Looking Back and Looking Ahead. Androgens: Clinical Research and Therapeutics.Dec 2022.2-13. https://www.liebertpub.com/doi/10.1089/andro.2021.0030

    • Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011 Jan;27(1):39-48. doi: 10.3109/09513590.2010.487597. PMID: 21142609. https://pubmed.ncbi.nlm.nih.gov/21142609/

    • Glaser R, Dimitrakakis C. Testosterone therapy in women: myths and misconceptions. Maturitas. 2013 Mar;74(3):230-4. doi: 10.1016/j.maturitas.2013.01.003. Epub 2013 Feb 4. PMID: 23380529. https://pubmed.ncbi.nlm.nih.gov/23380529/

  • • Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999 Dec;44(12):1012-20. PMID: 10649811. https://pubmed.ncbi.nlm.nih.gov/10649811/

    • Susan L. Greenspan, MD; Neil M. Resnick, MD; Robert A. Parker, ScD. Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women A Randomized Controlled Trial. JAMA. 2003;289(19):2525-2533. doi:10.1001/jama.289.19.2525 https://jamanetwork.com/journals/jama/fullarticle/196582

  • • https://www.instagram.com/reel/CourZ8cAvSO/?igshid=MDJmNzVkMjY%3D

  • 1. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-427; doi: 10.1016/s0140-6736(03)14065-2. https://pubmed.ncbi.nlm.nih.gov/12927427/

    2. Davis S, Moreau M, Kroll R. Testosterone for low libido in postmenopausal women not taking estrogen. N Eng J Med 2008;359(19):2005-2017; doi:10.1056/NEJMoa0707302. https://pubmed.ncbi.nlm.nih.gov/18987368/

    3. Davis SR, McCloud P, Strauss BJ, et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 1995;21(3):227-236; doi: 10.1016/0378-5122(94)00898-h. https://pubmed.ncbi.nlm.nih.gov/7616872/

    4. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019;365:1652; doi: 10.1136/bmj.l1652. https://pubmed.ncbi.nlm.nih.gov/31088823/

    5. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995;16(5):499-503; doi: 10.1016/8756-3282(95)00075-o. https://pubmed.ncbi.nlm.nih.gov/7654464/

    6. Glaser R, Dimitrakakis C Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrazole: a prospective, observational study. Maturitas 2013;76(4);342-349; doi:10.1016/j.maturitas.2013.08.002. https://pubmed.ncbi.nlm.nih.gov/24028858/

    7. Glaser R, Dimitrakakis C. Testosterone Therapy in Women: Myths and Misconceptions. Maturitas2013; 74;230-4; doi: 10.1016/jmaturitas.2013.01.003 https://pubmed.ncbi.nlm.nih.gov/23380529/

    8. Glaser R, Kalantaridou S, Dimitrakakis C. Testosterone implants in woman: Pharmacological dosing for a physiologic effect. Maturitas 2013;74(2):179-184; doi: 10.1016/j.maturitas.2012.11.004. https://pubmed.ncbi.nlm.nih.gov/23265303/

    9. Glaser, R, York AE, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas 2011;68(4):355-361; doi: 10.1016/j.maturitas.2010.12.001. https://pubmed.ncbi.nlm.nih.gov/21177051/

    10. Greenblatt R, Suran R. Indications for hormone pellets in therapy of endocrine and gynecic disorders. Am J Obstet Gynecol 1949;57(2):294-301; doi: 10.1016/0002-9378(49)90429-9. https://pubmed.ncbi.nlm.nih.gov/18123090/

    11. Holland EF, Studd JW, Mansell JP, et al. Changes in collagen composition and cross-links in bone and skin of osteoporotic postmenopausal women treated with percutaneous estradiol implants. Obstet Gynecol 1994;47(1)88-88; doi: 10.1016/0020-7292(94)90486-3. https://pubmed.ncbi.nlm.nih.gov/8290178/

    12. Khosla S, Oursler MJ, Monroe D. Estrogen and the skeleton. Trends Endocrinol Metab2012;23(11):576-581; doi: 10.1016/j.tem.2012.03.008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424385/

    13. Langer RD. The evidence base for HRT: what can we believe?. Climacteric2017; doi: 10.1080/13697137.2017.1280251 https://pubmed.ncbi.nlm.nih.gov/28281363/

    14. Misra M, Katzman D, Miller K, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res. 2011;26(10):2430-2438; doi: 10.1002/jbmr.447. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304439/

    15. Morgentaler A, Miner M, Caliber M et al. Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clin Proc.2015;90(2):224-251; doi: 10.1016/j.mayocp.2014.10.011 https://pubmed.ncbi.nlm.nih.gov/25636998/

    16. Nachtigall L, Casson P, Lucas J, et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011;27(1):39-48; doi: 10.3109/09513590.2010.487597. https://pubmed.ncbi.nlm.nih.gov/21142609/

    17. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the Adore study. Climacteric 2010;13(2):121-131; doi: 10.3109/13697131003675922. https://pubmed.ncbi.nlm.nih.gov/20166859/

    18. Rossouw J, Anderson G, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333; doi: 10.1001/jama.288.3.321. https://pubmed.ncbi.nlm.nih.gov/12117397/

    19. Savvas M, Studd JW, Fogelman I, et al. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ 1988;297(6644):331-333; doi: 10.1136/bmj.297.6644.331.

    20. Sinnesael M, Boonen S, Claessens F, et al. Testosterone and the male skeleton: a dual mode of action. J Osteoporos 2011;2011:240328; doi: 10.4061/2011/240328. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173882/

    21. Studd J, Savvas M, Watson N, et al. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol 1990;163(5 Pt 1):1474-1479; doi: 10.1016/0002-9378(90)90608-a. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685269/

    22. Traish A, Morgentaler A. Androgen Thereapyin Women with Testosterone Insufficiency: Looking Back and Looking Ahead. Androgens2022;3.1;2-13; doi: 10.1089/andro.2021.0030 https://pubmed.ncbi.nlm.nih.gov/31687883/

    23. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004;25(3):389-425; doi: 10.1210/er.2003-0003. https://pubmed.ncbi.nlm.nih.gov/15180950/

  • https://thennt.com/